Furthermore, clinical trials have not comprehensively examined the efficacy of lipid-lowering drugs (i.e., statins, fibrates, and NPC1L1 inhibitors) for the treatment of NAFLD. This evidence concerns the gene NPC1L1 and metabolic dysfunction-associated steatotic liver disease.